Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Dyne Therapeutics (NASDAQ:DYN), a clinical-stage biotech company focused on neuromuscular diseases, has successfully completed its previously announced public offering of common stock. The company sold 27,878,788 shares at $8.25 per share, including the full exercise of the underwriters' option to purchase additional shares.
The offering generated gross proceeds of approximately $230.0 million before deducting underwriting discounts, commissions, and offering expenses. Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities served as joint book-running managers, with Jones acting as co-manager for the offering.
Dyne Therapeutics (NASDAQ:DYN), una societ脿 biotecnologica in fase clinica specializzata in malattie neuromuscolari, ha completato con successo l'offerta pubblica di azioni ordinarie precedentemente annunciata. La societ脿 ha venduto 27.878.788 azioni a 8,25 dollari per azione, inclusa l'esercitazione completa dell'opzione degli underwriter per l'acquisto di azioni aggiuntive.
L'offerta ha generato proventi lordi di circa 230,0 milioni di dollari prima della detrazione di sconti, commissioni e spese di offerta. Morgan Stanley, Jefferies, Stifel e Guggenheim Securities hanno agito come joint book-running managers, mentre Jones ha svolto il ruolo di co-manager per l'offerta.
Dyne Therapeutics (NASDAQ:DYN), una empresa biotecnol贸gica en etapa cl铆nica enfocada en enfermedades neuromusculares, ha completado con 茅xito su oferta p煤blica previamente anunciada de acciones comunes. La compa帽铆a vendi贸 27.878.788 acciones a 8,25 d贸lares por acci贸n, incluyendo el ejercicio total de la opci贸n de los suscriptores para comprar acciones adicionales.
La oferta gener贸 ingresos brutos de aproximadamente 230,0 millones de d贸lares antes de deducir descuentos, comisiones y gastos de la oferta. Morgan Stanley, Jefferies, Stifel y Guggenheim Securities actuaron como gestores conjuntos principales, con Jones como co-gestor de la oferta.
Dyne Therapeutics (NASDAQ:DYN)電� 鞁犼步攴� 歆堩櫂鞐� 欷戩爯鞚� 霊� 鞛勳儊 雼硠 氚旍澊鞓ろ厤 須岇偓搿�, 鞚挫爠鞐� 氚滍憸頃� 氤错喌欤� 瓿店皽 氇鞚� 靹标车鞝侅溂搿� 鞕勲頄堨姷雼堧嫟. 須岇偓電� 欤茧嫻 8.25雼煬鞐� 27,878,788欤�毳� 韺愲Г頄堨溂氅�, 鞚胳垬鞚鸽摛鞚� 於旉皜 欤检嫕 毵れ瀰 鞓奠厴鞚� 鞝勳暋 頄夓偓頄堨姷雼堧嫟.
鞚措矆 瓿惦毳� 韱淀暣 鞚胳垬 靾橃垬耄�, 頃犾澑 氚� 瓿惦 牍勳毄鞚� 瓿奠牅頃橁赴 鞝� 鞎� 2鞏� 3觳滊 雼煬鞚� 齑� 靾橃澋鞚� 彀届稖頄堨姷雼堧嫟. Morgan Stanley, Jefferies, Stifel, Guggenheim Securities臧� 瓿惦彊 欤缄磤靷 彀胳棳頄堨溂氅�, Jones電� 瓿惦彊 甏�毽瀽 鞐暊鞚� 毵§晿鞀惦媹雼�.
Dyne Therapeutics (NASDAQ:DYN), une soci茅t茅 biotechnologique en phase clinique sp茅cialis茅e dans les maladies neuromusculaires, a men茅 脿 bien son offre publique d鈥檃ctions ordinaires pr茅c茅demment annonc茅e. La soci茅t茅 a vendu 27 878 788 actions au prix de 8,25 dollars par action, incluant l'exercice complet de l'option des souscripteurs d'acheter des actions suppl茅mentaires.
L鈥檕ffre a g茅n茅r茅 des produits bruts d鈥檈nviron 230,0 millions de dollars avant d茅duction des remises, commissions et frais li茅s 脿 l鈥檕ffre. Morgan Stanley, Jefferies, Stifel et Guggenheim Securities ont agi en tant que gestionnaires principaux conjoints, avec Jones en tant que co-gestionnaire de l鈥檕ffre.
Dyne Therapeutics (NASDAQ:DYN), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf neuromuskul盲re Erkrankungen, hat erfolgreich sein zuvor angek眉ndigtes 枚ffentliches Angebot von Stammaktien abgeschlossen. Das Unternehmen verkaufte 27.878.788 Aktien zu je 8,25 USD, einschlie脽lich der vollst盲ndigen Aus眉bung der Option der Underwriter zum Kauf zus盲tzlicher Aktien.
Das Angebot generierte Bruttoerl枚se von etwa 230,0 Millionen USD vor Abzug von Underwriting-Rabatten, Provisionen und Angebotskosten. Morgan Stanley, Jefferies, Stifel und Guggenheim Securities fungierten als gemeinsame Bookrunner, w盲hrend Jones als Co-Manager des Angebots t盲tig war.
- Raised significant capital of $230.0 million through the offering
- Full exercise of underwriters' option indicates strong demand
- Strengthened balance sheet to support clinical-stage pipeline development
- Potential dilution for existing shareholders due to issuance of 27.9 million new shares
Insights
Dyne secured $230M through stock offering at $8.25/share, substantially strengthening its financial position for advancing neuromuscular disease therapies.
Dyne Therapeutics has successfully closed a
The pricing at
For a clinical-stage biotech company without marketed products, access to capital is absolutely essential. This offering substantially strengthens Dyne's financial position, likely extending its operational runway by several quarters or potentially years, depending on burn rate. The proceeds will presumably accelerate the development of Dyne's pipeline focused on genetically driven neuromuscular diseases, potentially funding pivotal trials and advancing candidates toward potential regulatory approvals.
While this offering will cause dilution for existing shareholders, the enhanced financial stability and reduced financing risk likely outweigh dilution concerns in the near term. The company now has significantly more resources to pursue value-creating clinical milestones without immediate financing pressure.
WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics,听Inc. (Nasdaq:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced underwritten public offering of 27,878,788 shares of its common stock at a public offering price of
Morgan Stanley, Jefferies, Stifel and Guggenheim Securities acted as joint book-running managers for the offering. Jones acted as co-manager for the offering.
The offering was made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (鈥淪EC鈥�) on March 5, 2024 and became automatically effective upon filing. The offering was made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC鈥檚 website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at [email protected]; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected].
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.
Contacts:
听
Investors
Mia Tobias
[email protected]
781-317-0353
Media
Stacy Nartker
[email protected]
781-317-1938
FAQ
How much money did Dyne Therapeutics (DYN) raise in its July 2025 public offering?
What was the share price for Dyne Therapeutics' public offering in July 2025?
How many shares did Dyne Therapeutics sell in its July 2025 offering?
Who were the underwriters for Dyne Therapeutics' July 2025 public offering?
What is Dyne Therapeutics' main business focus?
